Iovance Biotherapeutics
IOVA
6.90
-0.41
-5.61%
Iovance Biotherapeutics
US · IOVA
#1864 by market cap
Listed 1970
6.90
-0.41
-5.61%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:59
About Iovance Biotherapeutics
Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.
- Founded
- 2007
- CEO
- Dr. Frederick G. Vogt, J.D.
- Employees
- 975
- Headquarters
- San Carlos, California, United States of America
- Fiscal year end
- 12-31
- Website
- iovance.com
Company profile
- Exchange
- US
- Symbol
- IOVA
- Market-cap rank
- #1864
- Listing date
- 1970-01-01
- Market cap
- 3.19B
- Float cap
- 2.79B
- Shares out
- 462.66M
- Float shares
- 403.97M
Sectors & themes
Biotechnology
Fractional Shares JP
Quote time 2026-11-20 19:59:47 · For reference only, not investment advice and not tailored to your situation.
Iovance Biotherapeutics discussion 0 comments